Red Rock Resorts has broken ground on its new $750m Durango Station casino in Las Vegas.

The post Red Rock Breaks Ground on New $750m Casino in Las Vegas appeared first on VegasSlotsOnline News.

Primex Finance is a decentralized finance protocol for digital assets, which enables DEX-agnostic cross-margin trading with scoring systems. DeFi is one of the most successful areas of blockchain-based products. The current problem with DeFi is the lack of trusted sources for lending and stable cross-chain interoperability. What is Primex Finance? The platform allows users to [...]

The post Primex Finance: Bringing Cross-DEX & Cross-Chain Trading to DeFi appeared first on Blockonomi.

TOKYO, Jan 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. CEO Naito represented pharmaceutical companies and highlighted the achievements of NTDs elimination activities by the industry and successes achieved by multi-sectoral partnerships. He also expressed Eisai's continued support for the elimination of NTDs towards the achievement of NTD road map 2021-2030 launched by the World Health Organization (WHO) last year. The 10th anniversary event aimed to recognize a decade of progress since the London Declaration, to confirm the strong commitment of stakeholders to continue the efforts for NTDs, and to strengthen endorsements from stakeholders to the Kigali Declaration on NTDs, the successor of the London Declaration which will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda.

Tremendous achievements have been made through public-private partnership since the launch of the London Declaration to 2020. The pharma industry has contributed to the elimination of NTDs via supply of medicines which resulted in donation of 13 billion high-quality treatments. Forty-three countries have eliminated at least one NTD and 600 million people no longer require interventions against NTDs. Despite such progress, more than 1.7 billion people remain threatened by NTDs.

In the event, CEO Haruo Naito said, "Our initiatives toward NTDs elimination are rooted in the pharmaceutical company's fundamental mission to deliver medicines to those who need them to treat illness and save lives. While R&D for NTDs treatments have become more active after the London Declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. Utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure."

Under the London Declaration, Eisai has been manufacturing and supplying diethylcarbamazine (DEC) tablets, one of the lymphatic filariasis (LF) treatments, free of charge to the WHO for the elimination of LF. To date, 2.05 billion DEC tablets manufactured at Eisai's Vizag Plant in India have been supplied to 29 countries (as of January 2022). Although LF has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. Eisai is committed to providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries. In addition to the supply of DEC tablets, Eisai is working on various initiatives such as support for the mass drug administrations (MDA), disease awareness and improvements in sanitation.

Furthermore, Eisai is proactively engaged in development of new treatments for NTDs through partnerships with global research organizations. Utilizing the funding from the Global Health Innovative Technology Fund (GHIT Fund) and others, Eisai is conducting joint development of new treatments such as a new treatment for LF in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the Drugs for Neglected Diseases initiative (DNDi).

Eisai commits to the Kigali Declaration and strengthens collaborations with global partners to tackle NTDs towards the achievement of NTD road map 2021-2030.

Based on human health care (hhc) philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries. Once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. Eisai considers this to be a long-term investment in creating the markets for the future. Eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including NTDs and facilitate initiatives to improve access to medicine such as support for MDAs and disease awareness activities. Through these initiatives, Eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.

About Neglected Tropic Diseases (NTDs)

Neglected Tropic Diseases (NTDs) include 20 diseases that the WHO identifies as tropical diseases which human race must overcome. More than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of NTDs infection. The spread of NTDs is mainly caused by poor hygienic conditions associated with poverty. Infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. In the worst cases, NTDs may also result in death. The prevalence of NTDs is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.
The following 20 NTDs have been designated by WHO for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (Hansen's disease], Chagas disease, human African trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.

About London Declaration on Neglected Tropical Diseases

On January 30, 2012, the CEOs of 13 pharmaceutical companies*, the Bill & Melinda Gates Foundation, WHO, the U.S. Agency for International Development (USAID), the U.K. Department for International Development (DFID), the World Bank, and officials from NTD-endemic countries gathered in London to pledge their support for a coordinated effort to combat 10 NTDs**. The London Declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat NTDs.

Commemorating the London Declaration, January 30 has been designated as the World NTD Day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of NTDs. Eisai is sponsoring the light up of Tokyo Tower to raise disease awareness and disseminate the importance of eliminating NTDs.

* Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, GlaxonSmithKline, Gilead, Johnson & Johnson, Merck (Merck KGaA: Germany), Merck Sharp & Dhome, Novartis, Pfizer, Sanofi
** Guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human African trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, Chagas disease, and visceral leishmaniasis

About Kigali Declaration on Neglected Tropical Diseases

As the successor of the London Declaration on NTDs launched in 2012, the Kigali Declaration represents a collective commitment from stakeholders to fight against NTDs. With the endorsements from stakeholders being initiated at the online event entitled "100% COMMITTED to End NTDs", a campaign to commemorate the 10th year anniversary of the London Declaration held on January 27, 2022, the Kigali Declaration will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda. To achieve the WHO's NTD roadmap 2021-2030, the Kigali Declaration aims to tackle NTDs comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics for NTDs and ensuring equitable access to these NTDs related products and services.

About Lymphatic Filariasis

Lymphatic filariasis (LF) is an NTD transmitted to humans via carrier mosquitoes. LF causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. As a result, patients suffer mental, social and financial losses. It is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of LF. Elimination of LF is possible by stopping the spread of the infection through MDAs of three types of LF treatments including DEC tablets.

About Eisai's Commitment to Improving Global Access to Medicines including LF Elimination Program

In line with its hhc philosophy, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

In November 2010, Eisai agreed to supply a total of 2.2 billion DEC tablets to the WHO free of charge by 2020, as there was a global shortage of high-quality DEC tablets for use in MDAs. In 2012, Eisai became the only Japanese company to participate in the London Declaration, a coordinated effort to eliminate 10 NTDs and the largest public-private partnership of its kind in the field of global health. At the London Declaration's fifth anniversary event held in April 2017, Eisai announced its plan to supply DEC tablets continuously beyond 2020, until LF is eliminated in all endemic countries where DEC tablets are needed.

Eisai has supplied 2.05 billion tablets to 29 countries through the WHO's elimination program (as of January 2022). Furthermore, in order to support the smooth implementation of the WHO's MDA programs, Eisai is engaging in initiatives to raise public awareness of LF in endemic countries. Staff members of Eisai Group cooperate with the relevant representatives in endemic countries to eliminate LF as early as possible.

In addition to the above-mentioned initiatives, Eisai is moving ahead with new drug development projects targeting malaria and NTDs such as mycetoma and LF, based on partnerships with international non-profit organizations such as the Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV), as well as research organizations such as Liverpool School of Tropical Medicine, University of Kentucky, and the Broad Institute (please refer to the table above).

Furthermore, Eisai co-established the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public-private partnership to advance development of new health technologies for the developing world, is a member of the World Intellectual Property Organization (WIPO) Re:Search Consortium, an international joint enterprise for the development of treatments for NTDs, malaria and tuberculosis led by WIPO, is a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, and is participating in the Access Accelerated initiative to promote prevention and treatment of non-communicable diseases.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022.

Stephen M. Soble joins TerraScale's Board of Directors, bringing with him decades of experience representing pre-eminent U.S. corporations, governments, investors, manufacturing companies and...

(PRWeb January 27, 2022)

Read the full story at https://www.prweb.com/releases/2022/01/prweb18458931.htm

Two weeks ago, the state's Revenue Department revealed a new record that has been attained with the state's total yearly cannabis sales. The agency made this announcement on its website and across all of its social media platforms. The statement says that Colorado has crossed the $2 billion mark in tax and fee revenues. The state has also sold off about $12 billion in cannabis sales from the start of operations to date. The major record broken was the collection of $423 million in revenue from the total sales made throughout the year. In 2020, this total amount generated was $387 million (which was also a new record alert at the time).

As enterprise data security concerns grow, security experts urge businesses to back up their GitLab, GitHub, and BitBucket repositories.

Cardano (ADA) is a third-generation blockchain. What does that mean? In a nutshell, it builds on all the lessons learned from other coins to create a layered and distributed computing platform that places a special emphasis on security and engineering rigour. Cardano was officially launched in September 2017 under the so-called ‘Byron’ bootstrap phase. It […]

The post Cardano Deep Dive: Info you NEED about Cardano and ADA appeared first on Coin Bureau.

Bricktrade, the UK’s first tokenised real estate investment platform, are proud to announce they have recently partnered with

Sky Mavis pointed out that the goal of builders program is to further strengthen the community’s ability to create gaming experiences and tools, while managing risk to their community members, and their gaming network at-large.

The post Axie Infinity Launches Builders Program appeared first on BitPinas.

Microsoft have gone and done it again, announcing the intended acquisition of Activision Blizzard in a move that will have a potentially huge impact on the future of the games industry. What does this really mean though? Will Call of Duty now be an Xbox exclusive? The Deal of the Century? First things first, the deal itself is huge. Microsoft and Activision Blizzard’s respective boards have agreed to a sale worth a whopping $68.7 billion. That’s just stupid money. That’s the kind of money that we used to only really see with the fundamentals of everyday life, when mobile phone companies merge or separate, when energy companies combine, when car manufacturers or pharmaceuticals unite. That thinking is old hat now. The tech and entertainment companies are coming and they want to own… stuff. Just all the stuff, please. Yeah, more stuff. Who doesn’t love having loads and loads of stuff? Disney certainly likes having stuff, having picked up Marvel on the cheap and turned its properties into a never-ending stream of films and TV shows, then snagged Star Wars for a now laughably small $4 billion, and eventually setting its sights on beefing up its new streaming service by acquiring media rival 21st Century Fox for $71.3 billion in 2018. In the realms of video games, we have widespread investment from Chinese conglomerates, we have Embracer Group buying up everything in sight, and Sony and Microsoft both seeking to expand their first party studios. $68.7 billion might feel like a huge sum for Activision Blizzard, but it’s actually a good deal for Microsoft. ABK has exploded in value over the past decade, making it a part of the S&P 500 index which charts the 500 biggest companies in the US. This time last year, Activision Blizzard’s market cap was about to hit an all-time high of $80 billion on 12th February 2021, though typically hovering around $70 billion for the first half of the year. It hasn’t stayed that way, though. Something happened around the middle of 2021 that saw the company’s valuation slide from that $70 billion mark to under $50 billion. Part of that is purely financial – delays to game releases from Blizzard amongst them – but another part is the scandal that has surrounded the company like someone filled Bobby Kotick’s pockets with rotten eggs. How can Microsoft make this money back? Simply put, they don’t need to. Activision’s 2020 revenue was $8 billion, but their operating income was $2.7 billion. At that rate, it would take 25 years to make the money back… but that’s really beside the point for Microsoft. This is about key, strategic content that gives them a further competitive advantage in a growing market. Oh, and Microsoft had $120 billion in the bank in 2020 and an operating income of $70 billion in 2021. They have plenty left over… Will he stay or will he go? Microsoft’s willingness to acquire Activision Blizzard means that they’re prepared to take on the job of cleaning up its reputation. For the time being, the company will continue to be run as normal by CEO Bobby Kotick and his team as they navigate lawsuits, striking workers and unionisation efforts. They have to carry on business as usual until the deal is approved. While the company has taken steps, ousting over 40 individuals in recent months for transgression, declaring a zero tolerance policy, and promising to make contracted workers full time, there’s still more work to be done. Kotick himself is a part of the problem, having previously drawn criticism for cutting the company’s workforce despite record profits in 2018, and also having allegedly been aware of allegations and done nothing to address them. The wording of the deal’s announcement states that Kotick will carry on, though certainly leaves the door open for him to leave as soon as the purchase is approved and completed or after a transition period. His position and reputation don’t feel tenable as a part of Microsoft and reports suggest that he is to leave after any deal is concluded. I’m sure some will be hoping the door hits him on the arse on the way out. Will everything go Xbox exclusive? Maybe? We just don’t know at this point, with Phil Spencer’s only comments so far being that he hopes to bring as much of Activision’s back catalogue into Xbox Game Pass as soon as possible. However, we can look at the company’s track record here. For one thing, Xbox has allowed recent acquisitions to see out their various contracts and obligations, from Psychonauts 2 coming to PS4 and Deathloop being a timed PS5 exclusive. Additionally, existing game releases have also been allowed to continue on, so Minecraft is available on every platform imaginable. However, exclusive content drives attachment, and that’s why Bethesda’s Starfield will be exclusive. Looking at Activision’s portfolio, we can speculate that they’d pick and choose different approaches depending on the game and franchise. Call of Duty: Warzone is a free-to-play offshoot that needs to reach as many people as possible, but that could go hand in hand with future paid games in the franchise becoming Xbox exclusive. Similarly, Overwatch 2’s unusual release plan as a semi-expansion to Overwatch could get the blue light to come to PlayStation, as it’s building on an already released game. Diablo IV, though? Bet on that being an Xbox exclusive if the release comes after the finalised acquisition. The one thing we can definitively say is that everything will be thrown into Xbox Game Pass. Will we get the “old” Blizzard back? And what about Activision? In a word, no, but first I have to explain the question. Many fans have become disillusioned with some of the decisions that Blizzard have made over the past decade. There’s a feeling that the company has become too corporate and lost touch with its fans when announcing things like the mobile-only Diablo Immortal, the disappointing rushed release of Warcraft III: Reforged, and subsequent disbanding of the team that worked on it. There’s no putting a genie like that back in the bottle, and considering some of the rot that was revealed last year, I don’t think we want that genie back. Blizzard will still remain a part of Activision Blizzard, which will be a separate division under Xbox, but there might not be the same push to hit release targets that could help restore some of the “when it’s ready” ethos that led to them striking gold with World of Warcraft and Overwatch. Similarly, the pressure could be lifted on Activision’s Call of Duty content mill. Needing a new COD every single year means that Activision now has pretty much every one of their studios making content for this franchise. That’s a crying shame when Toys for Bob has just shown what they can do with Crash Bandicoot 4, and Vicarious Visions (now a part of Blizzard) revived Tony Hawk’s Pro Skater 1+2 to great acclaim. Microsoft’s acquisitions so far have been to secure a diverse portfolio, and on the Activision side of the company, that’s not currently what’s happening. Will the acquisition be approved? This is the big question, and while there is increasing scrutiny over tech companies making huge purchases like this, I can’t see it being blocked by the European Commission or the US Securities and Exchange Commission that will be looking into the impact that this will have on the games industry. In particular, they’ll be looking at the rulings they received when acquiring Bethesda. Yes, the deal is almost ten times the size and the revenue that Activision Blizzard generates is much greater, but the argument will be that this does little to nothing to harming the diversity of games on offer across the industry and across competing platforms, and that Microsoft aren’t buying an erstwhile competitor. PlayStation will likely remain the dominant platform for the foreseeable future… though if Call of Duty goes X box exclusive, who could say what the future holds?

L.A.'s Plan to House LA set a goal of nearly half a million new housing units by October 2029. Foes have warned it will cause displacement.

In this blog, we will discuss what makes Python so popular, its features, and why you should consider Python as a programming language for your startup.